ICT Introduces Two New HRP Conjugate Stabilizer Formulations

Conjugate stabilizers prolong the shelf-life of conjugated antibodies and other proteins, enhancing their utility in ELISA and Western applications.

HRP (horseradish peroxidase) Conjugate Stabilizer formulations are used to dilute, store, and reconstitute HRP-conjugated antibodies while preserving native protein configuration and activity. This stabilization maintains the signal-generating capabilities of HRP-conjugated antibodies during storage, inhibits nonspecific binding, and minimizes background signal. The two newest HRP conjugate stabilizers join ICT's other protein-stabilizing reagents in the range of ELISA Solutions™ to optimize assay development.

UCSF Scientists Develop Cell Reprogramming Technique to Generate Hepatocytes for Therapeutic Use

Regenerative Medicine Research News:

The liver possesses some capacity to regenerate or heal itself after injury. When the liver is damaged beyond this capacity, a whole-liver transplant is the preferred treatment of many medical professionals, but the demand for donor livers far exceeds supply. Thus, scientists are developing regenerative medicine therapies to treat damaged livers.

Human hepatocytes have been generated in vitro from induced pluripotent stem cells (iPSC), but these cells do not adequately proliferate and function after transplantation into mouse models of liver damage for therapeutic success.

In a study published in Nature Feb 23, 2014, UCSF scientists describe how they developed an induced multipotent progenitor cell (iMPC) reprogramming technique to differentiate

ICT INTRODUCES TWO NEW ELISA BLOCKING BUFFER FORMULATIONS

Proper blocking of the unoccupied areas of ELISA plate wells is paramount to reducing immunoassay background noise and attaining an accurate test result. Two new blocking buffer formulations from ImmunoChemistry Technologies offer additional choices to researchers working to optimize their ELISAs.

Monster Block is a new, non-mammalian blocking buffer
formulation designed to reduce nonspecific binding in
all ELISA formats.

Alternative Block ELISA Blocking Buffer is a new all-synthetic ELISA blocking buffer free of proteins and detergents.

Monster Block Blocking Buffer is a new ELISA blocking buffer utilizing a heterogenous mixture of non-mammalian blocking agents with high blocking strength.

ICT's ELISA Blocking Buffer formulations reduce nonspecific binding of sample and assay components to the ELISA well while stabilizing the coated protein. Six formulations offer benefits to different assay situations:

General Blocker Blocking Buffer		BSA-Based
Neptune Block Blocking Buffer		Non-Mammalian
Monster Block Blocking Buffer		Non-Mammalian
SynBlock Block Blocking Buffer		Synthetic
Phosph-Free Block Blocking Buffer		Synthetic
Alternative Block Blocking Buffer		Synthetic

For economical evaluation of many formulations, ICT offers a Blocking Buffer Optimization Pack (BBOP), which allows researchers to try three different formulations at a reduced rate. Read more about all ELISA Blocking Buffers on Immunochemistry.com: http://www.immunochemistry.com/products/elisa-solutions-1/blocking-buffers.html

ICT offers a large portfolio of tools to improve and enhance ELISA performance, including Blocking Buffers, Wash Buffers, Plate Coating Buffers, Conjugate Stabilizers, Sample Diluents, Substrates, Stop Solutions, and ELISA Plates and Accessories. View our complete portfolio:
ELISA Solutions, Blocking Buffers, and More

Bright Minds, Bright Solutions. ImmunoChemistry Technologies’ mission is to advance scientific discovery by developing innovative products for apoptosis detection, cellular analysis, and immunoassay development.

Press Release, Dec 03, 2013: ImmunoChemistry Technologies Changes Ownership

Release Date: 
December 03, 2013 (All day)
For immediate release

ImmunoChemistry Technologies Changes Ownership

Biomedical laboratory developing proprietary and patented reagents for cancer research is now majority women-owned.

Sally Hed, ImmunoChemistry
Technologies VP of Marketing
and Operations

Minneapolis, MN - December 03, 2013 - ImmunoChemistry Technologies (ICT), a Minnesota-based biotechnology company that supplies unique biochemical laboratory reagents and assay tests to medical researchers, has changed ownership. Now majority women-owned, ICT develops new products to help researchers discover new treatments and drugs for cancer and other diseases affecting both animals and humans.

The privately held company is now majority owned by Sally Hed, VP of Marketing and Operations, and Carol Lee, secretary and board member. Dr. Brian W. Lee, Ph.D., president and co-founder, owns one-third of the company and is in charge of ICT’s research and development. ICT has consistently achieved double-digit growth thanks to a solid customer base with an international distributor network serving labs all over the world.

"Someday, doctors will be able to tell if the treatment is working within a matter of hours because they’ll be able to see on a molecular level how many cancer cells are dying in response to treatment," said Sally Hed, VP of Marketing and Operations.

First FLICA 660 Caspase-1 Assay Citations

THP-1 cells with activated caspase-1 enzyme (ICE) emit far-red
fluorescence after staining with FLICA 660 Caspase-1 Assay

Recent peer-reviewed articles in Journal of Hepatology and Journal of Leukocyte Biology validate the use of the new FLICA® 660 Caspase-1 Assay Kit for caspase-1 detection.

NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis

Win a $100 Product Credit Towards Apoptosis Assays and ELISA Solutions!

We're excited about our new tools for life science research, so we're having a Facebook drawing to award $100 product credits!

The product credit will be valid towards the purchase of any standard catalog item available through www.immunochemistry.com/products, including all of our new products.

Recent Publications Using FLICA Assays

Our FLICA® fluorescent caspase assays continue to be routinely referenced in customers' publications. Here are just a couple that have been released in recent weeks:
Apoptosis-Associated Speck-like Protein Containing a Caspase Recruitment Domain Inflammasomes Mediate IL-1β Response and Host Resistance to Trypanosoma cruzi Infection.Silva GK, Costa RS, Silveira TN, Caetano BC, Horta CV, Gutierrez FR, Guedes PM, Andrade WA, De Niz M, Gazzinelli RT, Zamboni DS, Silva JS. J Immunol. (2013). [Abstract]